Folate-based radiopharmaceuticals can be used in positron emission tomography (PET) imaging to detect folate receptors in brain tumours, researchers from the University of Turku report.
An advanced imaging method is showing promise as a way to improve the diagnosis of prostate cancer by giving clinicians a clearer view of suspected tumours during biopsy.
A novel imaging agent can reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for Covid-19. This may mitigate the issue of tracer uptake in lymph nodes associaed with the vaccine.
AI-based models for multimodality hybrid imaging have the potential to be a potent clinical tool but are currently held back by a lack of transparency and maturity, says Dr Irène Buvat, from the Laboratory of translational Imaging in Oncology, Institute Curie in Paris, France.
Dutch scientists have performed whole-body PET scans using a radioactively labeled antibody tracer against immune cells, to predict the effect of treatment with immune checkpoint inhibitors.
Using fluorodeoxyglucose positron emission tomography (FDG-PET) imaging may give insights into possible dose reductions in ongoing radiation therapy of head and neck cancer. A promising study to explore this option was presented at the 2022 ASTRO/ASCO Multidisciplinary Head and Cancer Symposium held in Phoenix, Arizona.
US researchers have developed a test to detect loss of myelin - a key contributor to many neurological diseases including multiple sclerosis, traumatic brain and spinal cord injuries, stroke, and dementia.
Diagnostic imaging in women’s health advances: PET/CT might provide a more accurate imaging alternative to CT in ovarian cancer. T2*-weighted MR imaging in deep endometriosis detection also shows promise, but ultimately falls flat.
A new positron emission tomography (PET) radiotracer can detect abdominal aortic aneurysms (AAAs) and potentially predict when they will rupture, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2021 Annual Meeting. Targeting a novel biomarker associated with AAA, the radiotracer is effective both in diagnosis and in providing information to assist in the…
Whole-body magnetic resonance imaging (WB-MRI) can detect prostate cancer and inform about treatment response and disease progression earlier and better than other imaging modalities. A Belgian expert will delve into the latest and future developments of the technique for prostate cancer and distant metastases imaging in a dedicated session at ECR. WB‐MRI and nuclear medicine -…
Hybrid PET/CT imaging can fully play to its strengths and steer treatment towards more effective procedures for diagnosing prostate cancer. The examination of the specific antigen PSMA with hybrid PET imaging enables treatment monitoring with significantly higher diagnostic accuracy than conventional imaging and therefore, Professor Clemens Cyran believes, will soon become the standard diagnostic…
To target ionised radiation as precisely as possible, imaging a tumour is vital in radiotherapy planning. ‘Today, imaging is used increasingly during the therapy itself,’ explained Professor Mark Ladd during the 51st annual meeting of the German Society for Medical Physics (DGMP).
A software tool to predict the most effective therapy for non-small cell lung cancer (NSCLC) developed by applying deep learning artificial intelligence (AI) to positron emission tomography/computed tomography (PET/CT) images has been developed by researchers at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. The tool is designed to provide a noninvasive, accurate method to…
Whole body diffusion-weighted magnetic resonance imaging (DW MRI) may aid in the assessment of cancer treatment response in children and youth at much lower levels of radiation than current approaches, suggests a small study funded by the National Institutes of Health. The results appear in Radiology. Researchers compared DW MRI, which measures the density of tumors by tracking the movement of…
Prostate-specific membrane antigen imaging should be the positron emission tomography imaging agent of choice for men who have a prostate cancer recurrence after radical prostatectomy, which needs to be detected and located. For these men, it should become the standard of care, new research shows.
During a European Society of Hybrid, Molecular and Translational Imaging (ESHI) session at ECR 2019, three speakers discussed the role of artificial intelligence (AI) in hybrid imaging. While AI and machine learning is supporting clinicians using hybrid techniques such as PET/CT, MR/PET, or ultrasound and CT, challenges remain in ‘training the machines’ to add value to radiologists’ and…
The first total-body positron emission tomography/computed tomography (PET/CT) that can acquire a 3D image of the human body in a single position received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in January 2019. Its forthcoming commercial availability for clinical use in the United States later this year is the milestone achievement of a multi-institutional consortium…
A first-in-human study reports that the novel positron emission tomography/computed tomography (PET/CT) tracer 18F-GP1 showed excellent image quality and a high detection rate for the diagnosis of acute venous thromboembolism (VTE). Well-tolerated in patients, 18F-GP1 PET/CT also identified blood clots in distal veins of the leg below the knee, where conventional imaging has limitations.
Researchers at Johns Hopkins Medicine have identified in live human brains new radioactive “tracer” molecules that bind to and “light up” tau tangles, a protein associated with a number of neurodegenerative diseases including Alzheimer’s disease and other related dementias.
